Skip to content

The study for the efficacy and safety of laser treatment for tattoo

The study for the efficacy and safety of laser treatment for tattoo

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017609
Enrollment
Unknown
Registered
2018-08-06
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tattoo

Interventions

Group 1:Picoway picosecond laser
Group 2:MedLite nanosecond laser

Sponsors

Dermatology Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy men and women aged 18 to 60 years; 2. Fitzpatrick Skin Type II-VI; 3. The duration of the tattoo is greater than one month; 4. The tattoo can be divided into two parts symmetrically; 5. Ability and willingness to follow all interviews, treatments and evaluations; 6. Be able to understand and provide written informed consent; 7. Women of childbearing age require reliable contraceptive methods to be used at least 3 months prior to the start of the study recruitment.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or planned pregnancy during the study; 2. lactating women; 3. Photoallergy to the near-infrared wavelength region; 4. Take medications that increase photosensitivity; 5. Light-induced epilepsy; 6. Oral isotretinoin is used within 6 weeks prior to the start of treatment or during the study; 7. Active local or systemic infections, or open wounds in the treated area; 8. A history of keloid formation or poor wound healing in areas of previous skin lesions; 9. There is skin lupus; 10. Active herpes simplex in the treatment area; 11. There are multiple dysplasia in the treatment area; 12. Any form of active malignancy during recruitment or during the study; 13. There are significant systemic diseases or obvious conditions in the treated area; 14. Participate in other equipment or drug studies within one month prior to the start of treatment or during the study; 15. Evidence of mental or intellectual abnormalities, prisoners, or any active drug or alcohol dependence; 16. According to the investigator, any condition in which the subject is treated as part of the study may be unsafe (for the subject or researcher).

Design outcomes

Primary

MeasureTime frame
Skin lesion removal efficiency;

Countries

China

Contacts

Public ContactTong Lin

Dermatology Hospital, Chinese Academy of Medical Sciences

ddlin@hotmail.com+86 13951902258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026